Systematic Review of Parotid Gland Sarcomas: Multi-Variate Analysis of Clinicopathologic Findings, Therapeutic Approaches and Oncological Outcomes That Affect Survival Rate

Simple Summary Primary sarcomas of the parotid gland are rare malignancies of mesenchymal origin for which there is no generally well-defined treatment guideline. The aim of this study was to analyze, through the review of the literature, the factors affecting the prognosis of patients with primary sarcoma of the parotid gland. Size/extension at the diagnosis and the sarcoma’s histotype were the most important prognostic factors. Multivariate analysis showed that surgery performed on the tumor was the only parameter affecting long-term survival. In particular, total parotidectomy with preservation or, in the most advanced cases, with the sacrifice of facial nerve should be performed at any age independently of tumor histology. Abstract The aim of this study was to systematically review the literature of sarcoma of the parotid gland in order to analyze the main factors affecting survival rate. A systematic literature review was performed between January 1990 to November 2021, and 88 patients affected by parotid gland sarcomas were included. The most common histological types were Rhabdomyosarcoma and Synovial Sarcoma. From our review, it emerges that primary sarcomas of the parotid glands are locally aggressive but show low tendency to metastasize to the lymph nodes of the neck and that surgery (i.e., total or radical parotidectomy) is the main approach for their treatment. The global overall survival (OS) is 52% at 5 years and 34.1% at 10 years. The OS for T1, T2, T3, T4 tumor at 5 years of follow up is 80.0%, 66.5%, 56.7% and 33.3%, respectively. Size/extension at the diagnosis and the sarcoma’s histotype are the most important prognostic factors. Multivariate analysis showed that surgery (total or radical parotidectomy) performed on the tumor (p = 0.0008) was the only parameter that significantly affected the OS. Among the other variables, age (younger), use of adjuvant therapy and lymph node metastasis showed borderline significative values (p = 0.05). Our analysis suggests that, when a primitive parotid sarcoma is diagnosed, total or radical parotidectomy should be performed at any age independent of tumor histology. Because regional lymph node metastases from parotid sarcomas are uncommon, alternative strategies (e.g., close follow-up by imaging and evaluation of sentinel lymph nodes) should be pursued before lymph node (selective/radical) dissection.

[1]  E. de' Campora,et al.  Acinic cell carcinoma of the parotid gland: Timeo Danaos et dona ferentes? A multicenter retrospective analysis focusing on survival outcome , 2022, European Archives of Oto-Rhino-Laryngology.

[2]  S. Ceccarelli,et al.  DNMT3A and DNMT3B Targeting as an Effective Radiosensitizing Strategy in Embryonal Rhabdomyosarcoma , 2021, Cells.

[3]  C. Gomez-Fernandez,et al.  Mesenchymal Neoplasms of Salivary Glands: A Clinicopathologic Study of 68 Cases , 2021, Head and Neck Pathology.

[4]  M. Cuéllar-Hubbe,et al.  Should metastatic lymph nodes be considered at the same clinical stage as distant metastasis in soft tissue sarcomas? , 2020, Cancer treatment and research communications.

[5]  S. Shaabani,et al.  Sarcoma treatment in the era of molecular medicine , 2020, EMBO molecular medicine.

[6]  A. Gronchi,et al.  Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine , 2020, CA: a cancer journal for clinicians.

[7]  J. Cates Staging soft tissue sarcoma of the head and neck: Evaluation of the AJCC 8th edition revised T classifications , 2019, Head & neck.

[8]  D. Schwartz,et al.  Impact of Adjuvant Radiotherapy for Malignant Salivary Gland Tumors , 2017, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[9]  W. Mendenhall,et al.  Indications for Salivary Gland Radiotherapy. , 2016, Advances in oto-rhino-laryngology.

[10]  R. Weber,et al.  Primary sarcomas of the salivary glands: Case series and literature review , 2013, Head & neck.

[11]  P. Casali,et al.  Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Kyung-Ja Cho,et al.  Mesenchymal neoplasms of the major salivary glands: clinicopathological features of 18 cases , 2008, European Archives of Oto-Rhino-Laryngology.

[13]  R. Rosenfeld,et al.  Levels of evidence in otolaryngology journals , 2005, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[14]  J. Shah,et al.  Head and Neck Soft Tissue Sarcomas: A Multivariate Analysis of Outcomes , 2004, Annals of Surgical Oncology.

[15]  M. Ballo,et al.  Prognostic factors for patients with localized soft‐tissue sarcoma treated with conservation surgery and radiation therapy , 2003, Cancer.

[16]  D. Kraus Sarcomas of the head and neck , 2002, Current oncology reports.

[17]  J. Batsakis,et al.  Primary sarcomas of the major salivary glands. , 1991, Archives of otolaryngology--head & neck surgery.

[18]  S. Weiss,et al.  Sarcomas and sarcomatoid neoplasms of the major salivary gland regions: A clinicopathologic and immunohistochemical study of 67 cases and review of the literature , 1986, Cancer.

[19]  D. Fitzwilliams Popliteal Aneurysm , 1937, Proceedings of the Royal Society of Medicine.